Device Trial Radar · NCT07362160
Clear Orthodontic Expander Versus Hyrax
Last checked: Nov 19, 2026Latest source record: Apr 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Feb 1, 2026
Primary completion
Nov 1, 2026
Study completion Feb 1, 2027
Sponsor
- Lead sponsor
- University of BaghdadAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 23, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 10 years, up to 14 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study will be conducted to evaluate the effectiveness of a clear expander fabricated from 2-mm biocompatible polyethylene terephthalate glycol (PETG) thermoforming material integrated with an expansion screw in achieving dental and skeletal expansion in adolescent patients, compared with the conventional Hyrax expander.
Conditions
- Malocclusion
- Narrow Maxilla
Interventions
New clear expanderDevice
All patients with a clear expander will be instructed to wear the appliance 24 hours a day, except during eating and cleaning. The expander will be activated twice daily (0.2 mm per turn). Patients will be provided with an instruction brochure and advised to use a reminder to ensure compliance. The expansion will continue until the desired amount of the maxillary arch expansion occurs when the maxillary first molars' palatal cusps occlude the lingual side of the mandibular first molar buccal cusps to overcome the expected relapse due to the elasticity of the palatal soft tissue.
Hyrax expanderDevice
The activation protocol for the Hyrax expander will be the same in all patients, twice daily (0.2 mm per turn). The expansion will continue until the desired amount of the maxillary arch expansion occurs when the maxillary first molars' palatal cusps occlude the lingual side of the mandibular first molar buccal cusps to overcome the expected relapse due to the elasticity of the palatal soft tissue.
Primary outcomes
What the sponsor says the trial is designed to measure.
- CBCT evaluationTime frame: pre-treatment (T0) and immediately post-treatment (T1) around one to two months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Baghdad/Collage of Dentistry
Baghdad, Al-Rusafa, Bab Al-moadham, Iraq · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.